Chardan Capital maintains Buy rating on Agenus, $40 price target

Chardan Capital kept its Buy rating on Agenus with a $40 price target, implying a 525% upside from the Oct 21 close. The firm cited Agenus's strong development pipeline, including botensilimab and balstilimab, and positive clinical data expectations from studies like NEST and UNICORN.

Original reporting
Published Oct 22, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chardan Capital maintains Buy rating on Agenus, $40 price target — source image
Decision brief

The 30-second read

$AGENBullishLow
01

Why it matters

A strong buy rating with a high target can trigger short-term buying pressure, but execution risk remains.

02

Market read

The upgrade may prompt short-term price appreciation for AGEN.

03

What to watch

Potential regulatory delays and competition in the neoadjuvant colon cancer space.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst rating updates are common catalysts for small-cap biotech stocks.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Chardan Capital maintained a Buy rating on Agenus and set a new $40 price target, implying a 525% upside.

Expected impact

likely upward pressure as investors price in the large upside potential

Evidence & confidence

The rating change and aggressive target are fresh analyst opinions that can attract new demand.

Market effects

May lift sentiment for biotech and immunotherapy peers.

Limited to US-listed biotech space.

Minor, confined to sector-specific investors.

Counterpoint

The $40 target may be overly optimistic given early-stage trial risk.

Key entities

  • Chardan Capital

    Equity research firm that issued the rating.

  • Agenus Inc.

    Biotech company developing immunotherapy candidates.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.